AIM ImmunoTech Inc (NYSE:AIM) CEO Tom Equels has welcomed positive data from a study using Ampligen to treat advanced and metastatic pancreatic cancer patients, which improved their median survival rates. In the single-center named 42 patient program, the immuno-pharma company said patients with locally advanced pancreatic cancer (LAPC) or metastatic disease were treated with Ampligen for six weeks at two doses per week with 400 miligrams (mg) per infusion.
AIM ImmunoTech hails positive data from Ampligen study on advanced, metastatic pancreatic cancer
